📚 Latest News : "SURMOUNT-1 Analysis: Tirzepatide Effective for Common Genetic Obesity Subtype". 🔓Access it here 👉

💡GLP-1 RAs in #HFrEF & #obesity. 🎙️Dr @VarunSundaram4 shares insights from the PRAISE-HFrEF study, revealing no increased risk of HF hospitalisation or mortality with GLP-1 RA treatment vs placebo. 📽️ Watch in full 👉 #GLP1 #HeartFailure #CVRM #CardioEd

Join millions who have switched to Grok.

⚖️ Balancing #aldosterone and potassium in #HeartFailure care. 📄Access Here 👉 ✅This review explores #dyskalaemia management strategies including #potassium binders, aldosterone-modulating therapies, treatment limitations & more!. #MRAs #CVRM #CardioEd

📚 Latest News : "DASH Diet Tailored for Diabetes Significantly Improves Glycaemic Control". 📚 A modified DASH diet significantly improves glycaemic control and time in range for people with type 2 diabetes, a new randomised trial finds. 👉

💡Dr Leigh Perreault shares key takeaways from the #PATHWEIGH trial and how its structured roadmap for weight management in primary care eliminated a population weight gain trajectory. 📺 👉 #T2D #CVRM #CKM #CardioEd

📚 Latest News : "Multimodal AI Model Offers Deeper Insight into Glycaemic Risk Than HbA1c Alone". 🔓Access it here 👉

📚 Latest News : "UPDATE Trial: Minimally Processed Diet Superior for Weight Loss Within Healthy Eating Guidelines". 🔓Access it here 👉

📚 Latest News : "EAST-AFNET 4: Early Rhythm Control Effective in AF Patients with Obesity and Diabetes". 🔓Access it here 👉

📚Special collection now available in #CFRJournal!. 🫀 New Mineralocorticoid Receptor Antagonists/#Aldosterone Antagonists.Curated by Guest Editor Dr Vijay Chopra. 🔗 Access now 👉 #HF #HeartFailure #Finerenone #SGLT2 #CKM #CardioEd #Cardiology

📚 Latest News : "Semaglutide Modulates Key Pathways to Resolve MASH, Proteomic Analysis Reveals". 📚 New research reveals how semaglutide resolves MASH, identifying a unique 72-protein signature that suggests its benefits extend beyond weight loss. 👉

📽️FINEARTS-HF 🩺Dr @safchat shares insights from a post-hoc analysis of the FINEARTS-HF trial, revealing that finerenone's effects remained consistent regardless of kidney function. 📺 Watch here👉 #Finerenone #CardioEd #CVRM #ESC_HFA #HeartFailure

📚 Latest News : "Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows". 🔓Access it here 👉

🔍Exploring the role of #MRAs in #HeartFailure care. This featured review evaluates the evidence for #aldosterone antagonism across the full #HF spectrum. 📖 Access the #CFRJournal article 👉 🫀Where do MRAs offer the greatest benefit?. #HFrEF #HFpEF

📚 Latest News : "New Multi-Ancestry Polygenic Score Improves BMI and Obesity Prediction Across the Lifespan". 🔓Access it here 👉

📄This featured article explores both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice. 📖Access the #CFRJournal article 👉 #GLP1 #HFpEF #CVRM #CardioRenal

👣Advancing #PAD care with #GLP1 therapies. 📽️Drs @MarcBonaca & @hvanspall discuss how #semaglutide improved walking ability and QoL in pts with #T2D & PAD 👉 📽️Dr @Catgobears on GLP1 RAs reducing amputation risk in moderate PAD 👉

💡This key review in #CFRJournal explores the haemodynamic effects of #SGLT2i therapy in chronic #HF. 🔓📖Access now 👉 #HFpEF #HFrEF #CVRM #CardioEd #Finerenone #Dapagliflozin #Empagliflozin

📚 Latest News : "Total ApoB and Lp(a) Count Deemed Superior for CAD Risk Assessment". 📚 For assessing lipid-related cardiovascular risk, a new study suggests it's the total count of apoB and Lp(a) particles that matters most, not their size or type. 👉

💡Dr @MKIttlesonMD discusses key updates and recommendations from the 2025 ACC Scientific Statement on the Management of #Obesity in Adults with #HeartFailure. 📽️Watch here👉 💭What are the new recommendations?. #HF #CVRM #CardioEd

📚 Latest News : "Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death". 🔓Access it here 👉